Fusion Of Cells Patents (Class 435/449)
-
Patent number: 11918631Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.Type: GrantFiled: May 20, 2016Date of Patent: March 5, 2024Assignee: THE ROCKEFELLER UNIVERSITYInventors: David Bikard, Luciano Marraffini
-
Patent number: 11535824Abstract: The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT). There is increasing evidence that the epigenetic state of donor nuclei has a significant impact on potential of nuclear transfer embryos to develop into blastocysts, from which pluripotent stem cells are derived. Strategic application of histone agents, capable of altering epigenetic state such as methylation, allows zygotic activation and robust blastocyst generation.Type: GrantFiled: October 28, 2016Date of Patent: December 27, 2022Assignee: Sung Kwang Medical FoundationInventors: Young Gie Chung, Dong Ryul Lee, Jin Hee Eum
-
Patent number: 11357831Abstract: The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.Type: GrantFiled: November 1, 2019Date of Patent: June 14, 2022Assignees: INSTITUT PASTEUR, ELIGO BIOSCIENCEInventors: David Bikard, Lun Cui, Xavier Duportet, Jesus Fernandez Rodriguez
-
Patent number: 10513709Abstract: The present invention provides methods for making reconstructed diploid human oocytes comprising the diploid genome of a human somatic cell, and also methods for making human nuclear transfer embryos, human embryonic stem cells, and human differentiated cells therefrom. The present invention also provides reconstructed human oocytes, human nuclear transfer embryos, human embryonic stem cells, and differentiated cells made using such methods, as well as compositions and kits useful in performing such methods.Type: GrantFiled: February 13, 2018Date of Patent: December 24, 2019Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli
-
Patent number: 9914766Abstract: The present invention relates to a method for generating a plurality of different IgY antibodies, by immunizing each of a plurality of avian organisms of the same or different species with a composition comprising a plurality of different antigens, thereby generating a plurality of different IgY antibodies.Type: GrantFiled: September 23, 2014Date of Patent: March 13, 2018Assignee: Carviar ApSInventor: Janus Beierholm Larsen
-
Patent number: 9896699Abstract: The present invention provides methods for making reconstructed diploid human oocytes comprising the diploid genome of a human somatic cell, and also methods for making human nuclear transfer embryos, human embryonic stem cells, and human differentiated cells therefrom. The present invention also provides reconstructed human oocytes, human nuclear transfer embryos, human embryonic stem cells, and differentiated cells made using such methods, as well as compositions and kits useful in performing such methods.Type: GrantFiled: March 14, 2014Date of Patent: February 20, 2018Assignee: New York Stem Cell Foundation, Inc.Inventor: Dietrich M. Egli
-
Patent number: 9045761Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.Type: GrantFiled: December 11, 2012Date of Patent: June 2, 2015Assignee: Vaxiion Therapeutics, LLCInventors: Matthew J Giacalone, Stanley Maloy, Shingo Tsuji
-
Publication number: 20150112125Abstract: A method of sorting sperm cells and a method of producing at least one sexed embryo. The method of sorting sperm cells includes the steps of establishing a sheath fluid environment including a citrate for stained sperm cells, establishing a stream including stained sperm cells in said sheath fluid environment, sensing a property of the stained sperm cells, and discriminating between stained sperm cells for a desired sex characteristic. The method of producing at least one sexed embryo includes the steps for sorting sperm cells in addition to fertilizing at least one egg with the sexed sperm to form at least one sexed embryo.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Applicant: XY, LLCInventors: George E. Seidel, Lisa A. Herickhoff, John L. Schenk
-
Publication number: 20150082471Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.Type: ApplicationFiled: September 16, 2014Publication date: March 19, 2015Inventors: Marie-Cecile van de Lavoir, Robert Etches
-
Patent number: 8945878Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: September 6, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Publication number: 20150024496Abstract: Disclosed herein include embodiments related to delivery of molecular molecules by a sperm cell to an egg cell for expression, including transient expression, in a fertilized progeny. Further embodiments relate to computerized systems for assisting in the disclosed methods.Type: ApplicationFiled: July 19, 2013Publication date: January 22, 2015Inventors: Roderick A. Hyde, Tony S. Pan, Lowell L. Wood, JR.
-
Patent number: 8900870Abstract: A method of forming a hybridoma cell includes acoustically focusing antibody producing cells in a first channel having a first acoustic field so as to produce a single file line of antibody producing cells; acoustically focusing immortal cells in a second channel having a second acoustic field so as to produce a single file line of immortal cells; flowing the acoustically focused single file lines of antibody producing cells and immortal cells to a third channel having a third acoustic field configured to bring at least one antibody cell and at least one immortal cell into close enough proximity to permit them to fuse; and fusing the antibody producing cell and the immortal cell together by at least one of a chemical and an electrical means to form at least one hybridoma cell.Type: GrantFiled: September 26, 2008Date of Patent: December 2, 2014Assignee: Life Technologies CorporationInventors: Michael D. Ward, Gregory Kaduchak
-
Patent number: 8901099Abstract: It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includes Escherichia coli GroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.Type: GrantFiled: November 20, 2012Date of Patent: December 2, 2014Assignee: Sekisui Chemical Co., Ltd.Inventors: Joe Chiba, Jun-ichi Hata, Naoki Nishiguchi, Masahiro Furutani
-
Publication number: 20140308257Abstract: The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (“IVF”) procedures.Type: ApplicationFiled: December 5, 2013Publication date: October 16, 2014Applicant: New York Stem Cell FoundationInventor: Dietrich M. Egli
-
Patent number: 8859233Abstract: The present invention relates to a method for generating a plurality of different IgY antibodies, by immunizing each of a plurality of avian organisms of the same or different species with a composition comprising a plurality of different antigens, thereby generating a plurality of different IgY antibodies.Type: GrantFiled: May 1, 2007Date of Patent: October 14, 2014Assignee: Carviar APSInventor: Janus Beierholm Larsen
-
Publication number: 20140248700Abstract: An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.Type: ApplicationFiled: May 7, 2014Publication date: September 4, 2014Applicant: Advanced Cell TechnolgyInventors: Jose Cibelli, Michael West, Robert Lanza
-
Publication number: 20140249364Abstract: Ovarian germ-line-competent embryonic stem cells (GLC-ESC) are cultured, either in the presence or absence of a compound having estrogenic activity. The GLC-ESC are either collected prior to specific commitment or are permitted to remain in the culture medium for a time sufficient to develop into oocytes, and the oocytes may be fertilized by adding sperm to the culture medium. The fertilized oocytes may be permitted to develop into embryos, which may be transferred into the uterus of an adult human female or frozen for later use. The invention provides a method for obtaining by in vitro fertilization an embryo that is genetically related to a human female who is not producing oocytes.Type: ApplicationFiled: October 2, 2013Publication date: September 4, 2014Applicant: OVASCIENCE, INC.Inventors: Antonin BUKOVSKY, Michael R. CAUDLE
-
Publication number: 20140234968Abstract: Immunocompatible pluripotent stem cells (pSCs), which include cells compatible with different patient populations or patient-specific cells, find wide application in regenerative medicine therapies. Described herein are immunocompatible pSCs generated using techniques such as parthenogenesis resulting in cells possessing desired haplotypes of reduced zygosity, antigenically compatible with multiple patient populations, or nuclear transfer allowing generation of patient-specific cells. Methods described herein related to parthenogenesis, nuclear transfer, or pSC cell line generation. Also described herein are compositions of immunocompatible pSCs and cell lines generated by the aforementioned techniques.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Sung Kwang Medical FoundationInventors: Young Gie Chung, Dong Ryul Lee
-
Publication number: 20140199319Abstract: Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of IgG expressing B cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas.Type: ApplicationFiled: December 13, 2013Publication date: July 17, 2014Applicant: AbbVie, Inc.Inventors: Jane SEAGAL, Eve H. BARLOW, Chung-Ming HSIEH, Jeffrey Yen PAN, Shawn M. JENNINGS, Mary R. LEDDY, Archana B. THAKUR
-
Patent number: 8778349Abstract: The intrinsically disordered sequences—or “intrinsically disorded sequences” or IDSeq—proteins should be flexible to ensure a controlled interaction between proteins. In the development of the diseases, IDSeq are modified and polymerized. The invention describes the method of preparation of the drugs against cancers, the degenerative diseases and the infectious illness, by the induction of an immune reaction against IDSeq modified in a covalent way (IDSeqC) and polymerized (pIDSeqC), and leading to a new network of protein signaling, named here “misfoldome”, causing the diseases. The invention describes the preparation of vaccines by the use of polymers of IDSeqC. Peptides of the pIDSeqC are prepared in vitro, and introduced into a living organism to induce an immunological response, which eliminates the “misfoldome” and cures the diseases. The method is employed for the preparation of active or passive vaccines.Type: GrantFiled: October 30, 2008Date of Patent: July 15, 2014Inventor: Halina Malina
-
Patent number: 8735138Abstract: The present invention relates to methods for producing Saccharomyces strains that are capable of growth on xylose as a sole carbon source at a desired growth rate (such as at least one generation per 48 hours), strains made by such methods, and Saccharomyces strains that grow at a growth rate of at least one generation per 48 hours using xylose as a sole carbon source for growth made by non-recombinant methods.Type: GrantFiled: September 16, 2009Date of Patent: May 27, 2014Assignee: Microbiogen Pty LtdInventors: Philip John Bell, Paul Victor Attfield
-
Patent number: 8697446Abstract: The present invention relates to a cell fusion chamber in which two types of cells having different diameters are fused, the cell fusion chamber including: a cell fusion region in which cell fusion is carried out; a pair of electrodes formed by a conductor and disposed opposite to each other in the cell fusion region; and a partition wall having at least one fine pore; near the fine pore, a cell fusion device including a cell fusion container containing a cell fusion region; a pair of electrodes; a spacer; and an insulator disposed between the spacer and one of the electrodes and having at least one fine pore; and an electronic power supply which applies an alternating voltage and a voltage pulsed direct current to the electrodes, and a cell fusion method using the same.Type: GrantFiled: September 14, 2012Date of Patent: April 15, 2014Assignee: Tosoh CorporationInventors: Toru Futami, Takahiro Maruyama, Atsushi Morimoto
-
Publication number: 20140057299Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Ronghui Lin
-
Publication number: 20140057301Abstract: Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Publication number: 20140057305Abstract: Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057303Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Bart M. Remmerie, Rhys Salter, Matthew Garrett Donahue, Yong Gong
-
Publication number: 20140057297Abstract: Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.Type: ApplicationFiled: August 20, 2013Publication date: February 27, 2014Inventors: Eric Hryhorenko, Banumathi Sankaran, Thomas R. DeCory, Theresa Tubbs, Linda Colt, Maarten Vliegen, Pieter Rik Haspeslagh
-
Patent number: 8642330Abstract: Antibody compositions and methods for inhibition of the effects of gonadotropin hormones are provided. Methods for treating cancer and methods for regulating fertility are provided by administration of the antibody compositions to a mammalian subject in need thereof.Type: GrantFiled: August 8, 2006Date of Patent: February 4, 2014Assignee: Onconon, LLCInventors: Edwin P. Rock, Vernon C. Stevens, Pierre L. Triozzi
-
Publication number: 20140005366Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: ApplicationFiled: April 16, 2013Publication date: January 2, 2014Applicants: Cancer Research Technology Limited, Københavns UniversitetInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20130336939Abstract: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.Type: ApplicationFiled: January 31, 2012Publication date: December 19, 2013Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, TECHNION RESEARCH AND DEVELOPEMENT FOUNDATION LTD.Inventors: Benjamin Podbilewicz, Ori Avinoam, Judith M. White
-
Publication number: 20130302288Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: ApplicationFiled: April 18, 2013Publication date: November 14, 2013Applicant: Advanced Cell Technology, Inc.Inventor: Advanced Cell Technology, Inc.
-
Publication number: 20130276159Abstract: Provided are a method for preparing a mammalian ovum or embryo in which zona pellucida has been thinned or eliminated, and a method for fertilization using the mammalian ovum prepared by the aforementioned method. The method for thinning or eliminating zona pellucida of a mammalian ovum or embryo involves treating or culturing the mammalian ovum or embryo (such as an unfertilized ovum, a fertilized ovum, or an embryo in the early stages of development) in a culture medium containing a reducing agent having SH groups (such as reduced glutathione or DTT). The resulting mammalian ovum or embryo (such as an unfertilized ovum, a fertilized ovum, or an embryo in the early stages of development) in which zona pellucida has been thinned or eliminated is capable of realizing an improved fertilization rate and development rate when used for in vitro fertilization, transplantation of a fertilized ovum, or preparation of an embryo in the early stages of development used in the production of a genetically modified animal.Type: ApplicationFiled: September 12, 2011Publication date: October 17, 2013Inventors: Naomi Nakagata, Toru Takeo
-
Patent number: 8551715Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: February 11, 2011Date of Patent: October 8, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 8513486Abstract: The present invention discloses methods for cell nuclear transfer that comprise for example modification of zona pellucida of an oocyte, and/or sectioning of oocytes into several parts. The present invention also discloses methods for producing a genetically modified non-human mammal. Genetically modified non-human mammals obtainable by the disclosed methods are also within the scope of the present invention. Disclosed are also methods for cryopreservation of cells.Type: GrantFiled: September 8, 2006Date of Patent: August 20, 2013Assignee: Aarhus UniversitetInventors: Yutao Du, Lars Axel Bolund, Gabor Vajta, Peter Michael Kragh
-
Publication number: 20130177987Abstract: Disclosed are methods for producing class-switched, affinity-matured antibodies which include enriching an immunized cell population for GL7-positive cells and activating the enriched cells. The methods may be used to improve the efficiency of obtaining immortalized antigen-specific plasma cells or to improve the quality of molecularly cloned Ig heavy and light chains.Type: ApplicationFiled: June 25, 2012Publication date: July 11, 2013Applicant: NEOCLONE BIOTECHNOLOGY INTERNATIONAL, LLCInventors: Brian Schram, Rachel Kravitz
-
Publication number: 20130149784Abstract: An IVF system for successfully utilizing spermatozoa separated into X-chromosome bearing and into Y-chromosome bearing population for insemination. The IVF system includes fertilization medium that can shorten the time from insemination to cleavage and a portable incubator for the transportation of maturing oocytes and inseminated oocytes comprising a straw (19) and an incubation element (20) that can be sealed with a cap (22).Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicant: XY, LLCInventor: XY, LLC
-
Publication number: 20130150663Abstract: Improved flow cytometer system particularly adapted to use for sex-selected sperm sorting include enhanced sheath fluid and other strategies which minimize stress on the sperm cells, including a 2.9 percent sodium citrate sheath solution for bovine species and a hepes bovine gamete media for equine species. Improved collection systems and techniques for the process are described so that commercial applications of sperms samples as well as the resulting animals may be achieved.Type: ApplicationFiled: February 11, 2013Publication date: June 13, 2013Applicant: XY, LLCInventor: XY, LLC
-
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
Patent number: 8445229Abstract: The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.Type: GrantFiled: May 25, 2010Date of Patent: May 21, 2013Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Shaohong Liang, Nicholas C. Nicolaides, Philip M. Sass -
Publication number: 20130086702Abstract: The present invention provides manufacturing processes for biological replication of undifferentiated plant and animal cells and tissue in a weightless condition, including those systems used in current stem cell research and development and use of undifferentiated parenchyma in plants. The present invention further provides methods for adapting plants and animals to survive outside their native environments. In particular, undifferentiated cells from plants or animals are replicated under weightless conditions in which cell replication or proliferation is accelerated and sustained. Under such conditions, the undifferentiated cells can be “forced” to express sets of genes useful for survival in particular environmental conditions. In this manner, cells surviving prolonged exposure to specific environmental conditions can be selected for and cultivated to produce an organism adapted to that particular environment in an accelerated manner.Type: ApplicationFiled: July 14, 2011Publication date: April 4, 2013Applicant: Zero Gravity, Inc.Inventor: John W. Kennedy
-
Publication number: 20130065307Abstract: Methods for making human ES cells and human differentiated cells and tissues for transplantation are described, whereby the cells and tissues are created following somatic cell nuclear transfer. The nuclear transfer donor is genetically modified prior to nuclear transfer such that cells of at least one developmental lineage are de-differentiated, i.e., unable to develop, thereby resolving the ethical dilemmas involved in reprogramming somatic cells back to the embryonic stage. The method concomitantly directs differentiation such that the desired cells and tissues may be more readily isolated.Type: ApplicationFiled: April 16, 2012Publication date: March 14, 2013Inventor: Jose CIBELLI
-
Publication number: 20130052267Abstract: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods.Type: ApplicationFiled: July 27, 2012Publication date: February 28, 2013Inventors: Helen M. Blau, Kostandin Pajcini, Jason Pomerantz
-
Publication number: 20130034906Abstract: The invention relates to methods for assisted reproduction technology in mammals. Specifically the invention relates to methods for in vitro mammalian oocyte culture and oocyte maturation, in vitro fertilization, and in vitro embryo development.Type: ApplicationFiled: January 7, 2011Publication date: February 7, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Gary D. Smith, Shuichi Takayama, Charles Bormann, Yunseok Heo
-
Patent number: 8349807Abstract: It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includes Escherichia coli GroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.Type: GrantFiled: October 14, 2005Date of Patent: January 8, 2013Assignees: Joe Chiba, Sekisui Chemical Co., Ltd.Inventors: Joe Chiba, Jun-ichi Hata, Naoki Nishiguchi, Masahiro Furutani
-
Publication number: 20120322156Abstract: In accordance with the present invention, a family of membrane fusion protein and polynucleotides encoding the proteins have been identified. The proteins and nucleotides are derived from the family Reoviridae. Two membrane fusion proteins have been isolated from reoviruses isolated from poikilothermic hosts: the p14 protein from reptilian reovirus (RRV) isolated from python, and the p16 protein from aquareovirus (AQV) isolated from salmon. The genes encoding these proteins have been cloned and sequenced. Analysis of the amino acid sequences of these proteins show that both lack the typical fusion peptide motif found in other membrane fusion proteins. Expression of these proteins in cells results in cell-cell fusion.Type: ApplicationFiled: August 24, 2012Publication date: December 20, 2012Applicant: INNOVASCREEN, INC.Inventor: Roy Duncan
-
Publication number: 20120315651Abstract: Oogonial stem cell (OSC)-derived compositions, such as nuclear free cytoplasm or isolated mitochondria, and uses of OSC-derived compositions in autologous fertility-enhancing procedures are described.Type: ApplicationFiled: April 13, 2012Publication date: December 13, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: JONATHAN L. TILLY, DORI C. WOODS
-
Publication number: 20120308580Abstract: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Applicants: NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Antonio Bertoletti, Sastry Konduru Seetharama, Paul Anthony Macary, Soh Ha Chan, Chien Tei Too
-
Patent number: 8283132Abstract: The invention relates to a method for treating a biological cell (1) including a cytoskeleton (3) enveloped by a cell membrane (2). The method includes the following steps: the biological cell (1) and a tool (10) are mutually oriented such that the tool (10) comes into contact with the biological cell (1); the tool (10) and the biological cell (1) are displaced in relation to each other; and a gap is formed in the molecular composite of the cell membrane (2) of the biological cell (1). During the displacement of the tool (10), the cytoskeleton (3) of the biological cell (1) has a state of equilibrium. The invention also relates to a cell manipulator for carrying out the inventive method.Type: GrantFiled: November 2, 2005Date of Patent: October 9, 2012Assignee: Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forshung e.V.Inventors: Günter Fuhr, Hagen Thielecke
-
Patent number: 8268617Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: August 26, 2009Date of Patent: September 18, 2012Assignee: ImmunoGen, Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20120191163Abstract: A method of manipulating a living cell is disclosed. The method comprises, directing a pulsed optical field to at least one conductive nanoparticle present in the vicinity of the cell, so as to generate cavitations at or near the conductive nanoparticle at sufficient amount to effect at least one cell modification selected from the group consisting of cell-damage and cell-fusion.Type: ApplicationFiled: January 19, 2012Publication date: July 26, 2012Applicant: Technion Research & Development Foundation Ltd.Inventors: Dvir Yelin, Limor Minai, Daniella Yeheskely-Hayon
-
Patent number: 8216842Abstract: The present invention provides methods of enhancing hybridoma fusion efficiencies through cell synchronization of the fusion partners, in order to aid in production of antibodies.Type: GrantFiled: October 12, 2007Date of Patent: July 10, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Jill Giles-Komar, Michael Rycyzyn, Gregory Bannish